Chris Mancill

At Bristol Myers Squibb (BMS), Chris leads the company's Worldwide Value Access and Payment (VAP) and Health Economics & Outcomes Search (HEOR) function, which is focused on defining and articulating the value of the BMS portfolio to payers and other access stakeholders around the globe and developing innovative solutions to help ensure appropriate patient access. Immediately before moving into his current role, Chris led the VAP function at BMS in the United States. He has over 25 years of experience in access, pricing, government affairs, and reimbursement at the global and U.S. levels.

He has worked for leading biopharmaceutical companies ranging from a pre-commercial start-up to those with large market capitalizations and was the Senior Vice President and Head for Global Value Access & Policy at MorphoSys AG before joining BMS. Previously, Chris held executive leadership roles at the global and US market levels in access, public policy, and government affairs at Amgen and Merck KGaA. Chris also has an extensive consultancy background in access and public policy with Avalere, Covance, and Parexel, and prior to joining the industry, worked at the American Red Cross and the Healthcare Financial Management Association.

Chris has also served as a Board Member at the National Pharmaceutical Council (NPC) and has worked extensively with industry trade groups, including the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), on access and reimbursement issues. He is a graduate of the University of Virginia (Master of Arts, 1995) and Christopher Newport University (Bachelor of Arts, 1993).